Compare AHMA & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | AEON |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United Arab Emirates | United States |
| Employees | N/A | 8 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.8M |
| IPO Year | N/A | N/A |
| Metric | AHMA | AEON |
|---|---|---|
| Price | $1.33 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 6.4M | 140.7K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.38 |
| 52 Week High | $39.50 | $1.45 |
| Indicator | AHMA | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 55.85 |
| Support Level | $0.76 | $0.98 |
| Resistance Level | $8.47 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.33 | 0.02 |
| Stochastic Oscillator | 56.88 | 63.79 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.